Progress in the Study of Pediatric ALL

Contemporary minimal residual disease (MRD)-directed therapy together with improved central-nervous-system leukemia control and supportive care have increased 5-year survival rate above 90% in childhood acute lymphoblastic leukemia (ALL).1 Some of the recent advances in biology and treatment of childhood ALL will be mentioned in this review.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research